BACKGROUND: Despite being still invasive and challenging, technical improvement has resulted in broader and more frequent application of extracorporeal membrane oxygenation (ECMO), to prevent hypoxemia and to reduce invasiveness of mechanical ventilation (MV). Heparin-coated ECMO-circuits are currently standard of care, in addition to heparin based anticoagulation (AC) regimen guided by activated clotting time (ACT) or activated partial thromboplastin time (aPTT). Despite these advances, a reliable prediction of hemorrhage is difficult and the risk of hemorrhagic complication remains unfortunately high. We hypothesized, that there are coagulation parameters that are indices for a higher risk of hemorrhage under veno-venous (VV)-ECMO therapy. METHODS: Data from 36 patients with severe respiratory failure treated with VV-ECMO at a University Hospital intensive care unit (ICU) were analyzed retrospectively. Patients were separated into two groups based on severity of hemorrhagic complications and transfusion requirements. The following data were collected: demographics, hemodynamic data, coagulation samples, transfusion requirements, change of ECMO-circuit during treatment and adverse effects, including hemorrhage and thrombosis. RESULTS: In this study 74 hemorrhagic events were observed, one third of which were severe. Patients suffering from severe hemorrhage had a lower survival rate on VV-ECMO (43% vs. 91%; P=0.002) and in ICU (36% vs. 86%; P=0.002). SAPS II, factor VII and X were different between mild and severe hemorrhage group. CONCLUSIONS: Severe hemorrhage under VV-ECMO is associated with higher mortality. Only factor VII and X differed between groups. Further clinical studies are required to determine the timing of initiation and targets for AC therapies during VV-ECMO.
BACKGROUND: Despite being still invasive and challenging, technical improvement has resulted in broader and more frequent application of extracorporeal membrane oxygenation (ECMO), to prevent hypoxemia and to reduce invasiveness of mechanical ventilation (MV). Heparin-coated ECMO-circuits are currently standard of care, in addition to heparin based anticoagulation (AC) regimen guided by activated clotting time (ACT) or activated partial thromboplastin time (aPTT). Despite these advances, a reliable prediction of hemorrhage is difficult and the risk of hemorrhagic complication remains unfortunately high. We hypothesized, that there are coagulation parameters that are indices for a higher risk of hemorrhage under veno-venous (VV)-ECMO therapy. METHODS: Data from 36 patients with severe respiratory failure treated with VV-ECMO at a University Hospital intensive care unit (ICU) were analyzed retrospectively. Patients were separated into two groups based on severity of hemorrhagic complications and transfusion requirements. The following data were collected: demographics, hemodynamic data, coagulation samples, transfusion requirements, change of ECMO-circuit during treatment and adverse effects, including hemorrhage and thrombosis. RESULTS: In this study 74 hemorrhagic events were observed, one third of which were severe. Patients suffering from severe hemorrhage had a lower survival rate on VV-ECMO (43% vs. 91%; P=0.002) and in ICU (36% vs. 86%; P=0.002). SAPS II, factor VII and X were different between mild and severe hemorrhage group. CONCLUSIONS: Severe hemorrhage under VV-ECMO is associated with higher mortality. Only factor VII and X differed between groups. Further clinical studies are required to determine the timing of initiation and targets for AC therapies during VV-ECMO.
Authors: V Kasirajan; N G Smedira; J F McCarthy; F Casselman; N Boparai; P M McCarthy Journal: Eur J Cardiothorac Surg Date: 1999-04 Impact factor: 4.191
Authors: Nicolò Patroniti; Alberto Zangrillo; Federico Pappalardo; Adriano Peris; Giovanni Cianchi; Antonio Braschi; Giorgio A Iotti; Antonio Arcadipane; Giovanna Panarello; V Marco Ranieri; Pierpaolo Terragni; Massimo Antonelli; Luciano Gattinoni; Fabrizio Oleari; Antonio Pesenti Journal: Intensive Care Med Date: 2011-07-06 Impact factor: 17.440
Authors: Cécile Aubron; Joris DePuydt; François Belon; Michael Bailey; Matthieu Schmidt; Jayne Sheldrake; Deirdre Murphy; Carlos Scheinkestel; D Jamie Cooper; Gilles Capellier; Vincent Pellegrino; David Pilcher; Zoe McQuilten Journal: Ann Intensive Care Date: 2016-10-06 Impact factor: 6.925
Authors: Jose I Nunez; Andre F Gosling; Brian O'Gara; Kevin F Kennedy; Peter Rycus; Darryl Abrams; Daniel Brodie; Shahzad Shaefi; A Reshad Garan; E Wilson Grandin Journal: Intensive Care Med Date: 2021-12-18 Impact factor: 41.787
Authors: Olivier van Minnen; Annemieke Oude Lansink-Hartgring; Bas van den Boogaard; Judith van den Brule; Pierre Bulpa; Jeroen J H Bunge; Thijs S R Delnoij; Carlos V Elzo Kraemer; Marijn Kuijpers; Bernard Lambermont; Jacinta J Maas; Jesse de Metz; Isabelle Michaux; Ineke van de Pol; Marcel van de Poll; S Jorinde Raasveld; Matthias Raes; Dinis Dos Reis Miranda; Erik Scholten; Olivier Simonet; Fabio S Taccone; Frederic Vallot; Alexander P J Vlaar; Walter M van den Bergh Journal: Trials Date: 2022-05-16 Impact factor: 2.728
Authors: Jens Martin Poth; Jens-Christian Schewe; Christian Putensen; Stefan Felix Ehrentraut Journal: J Clin Med Date: 2022-03-31 Impact factor: 4.241
Authors: Mathias Schmandt; Tim R Glowka; Stefan Kreyer; Thomas Muders; Stefan Muenster; Nils Ulrich Theuerkauf; Jörg C Kalff; Christian Putensen; Jens-Christian Schewe; Stefan Felix Ehrentraut Journal: J Clin Med Date: 2021-03-02 Impact factor: 4.241